Combination strategies on the basis of immune checkpoint inhibitors in non–small-cell lung cancer: where do we stand?
M Qiao, T Jiang, S Ren, C Zhou - Clinical lung cancer, 2018 - Elsevier
The era of immune checkpoint inhibitors, especially programmed death-1 (PD-
1)/programmed death ligand-1 (PD-L1) antibodies in the treatment of advanced non–small …
1)/programmed death ligand-1 (PD-L1) antibodies in the treatment of advanced non–small …